- Home
- MULN vs OLMA Comparison
MULN vs OLMA Comparison
Compare MULN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- OLMA
- Stock Information
- Founded
- MULN 2014
- OLMA 2006
- Country
- MULN United States
- OLMA United States
- Employees
- MULN N/A
- OLMA N/A
- Industry
- MULN Auto Manufacturing
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- MULN Consumer Discretionary
- OLMA Health Care
- Exchange
- MULN Nasdaq
- OLMA Nasdaq
- Market Cap
- MULN 6.5M
- OLMA 299.7M
- IPO Year
- MULN N/A
- OLMA 2020
- Fundamental
- Price
- MULN $0.32
- OLMA $4.37
- Analyst Decision
- MULN
- OLMA Strong Buy
- Analyst Count
- MULN 0
- OLMA 4
- Target Price
- MULN N/A
- OLMA $24.50
- AVG Volume (30 Days)
- MULN 9.4M
- OLMA 1.1M
- Earning Date
- MULN 08-11-2025
- OLMA 08-05-2025
- Dividend Yield
- MULN N/A
- OLMA N/A
- EPS Growth
- MULN N/A
- OLMA N/A
- EPS
- MULN N/A
- OLMA N/A
- Revenue
- MULN $8,931,612.00
- OLMA N/A
- Revenue This Year
- MULN N/A
- OLMA N/A
- Revenue Next Year
- MULN N/A
- OLMA N/A
- P/E Ratio
- MULN N/A
- OLMA N/A
- Revenue Growth
- MULN 2136.62
- OLMA N/A
- 52 Week Low
- MULN $0.30
- OLMA $2.86
- 52 Week High
- MULN $150,000,000.00
- OLMA $16.62
- Technical
- Relative Strength Index (RSI)
- MULN 17.40
- OLMA 48.24
- Support Level
- MULN $1.62
- OLMA $4.45
- Resistance Level
- MULN $1.64
- OLMA $4.73
- Average True Range (ATR)
- MULN 0.50
- OLMA 0.31
- MACD
- MULN 120.62
- OLMA 0.03
- Stochastic Oscillator
- MULN 0.14
- OLMA 52.75
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.